2. Upon review of a patient's drug profile, which combination of medications would indicate a potential drug-drug interaction or therapeutic duplication?
Answer: B
Cetirizine and loratadine indicate a potential drug-drug interaction or therapeutic duplication.
Both cetirizine and loratadine are antihistamines used to treat allergic reactions and symptoms. When taken together, they can lead to an increased risk of side effects without providing additional therapeutic benefit, signifying a therapeutic duplication.
A) Hydralazine and loratadine
Hydralazine is an antihypertensive medication, while loratadine is an antihistamine. There is no known significant drug-drug interaction or therapeutic duplication between these two medications, as they serve different therapeutic purposes.
B) Cetirizine and loratadine
Cetirizine and loratadine are both second-generation antihistamines. Using them concurrently can lead to an increased risk of adverse effects such as sedation or dry mouth, without enhancing the therapeutic outcome, thus indicating a potential drug-drug interaction or therapeutic duplication.
C) Famotidine and cetirizine
Famotidine is an H2 receptor antagonist used for reducing stomach acid, while cetirizine is an antihistamine. These medications do not interact significantly, and they are used for different indications, so there is no therapeutic duplication or clinically relevant drug-drug interaction.
D) Hydralazine and famotidine
Hydralazine and famotidine also serve different therapeutic roles, with hydralazine being an antihypertensive agent and famotidine an acid reducer. There is no evidence of a drug-drug interaction or therapeutic duplication between these medications.
Conclusion
The combination of cetirizine and loratadine is the only option that indicates a potential drug-drug interaction or therapeutic duplication due to both being antihistamines. The other options consist of medications that do not significantly interact or duplicate therapies, confirming option B as the correct answer.